Cyprotex improves drug testing software

MACCLESFIELD-based drug testing company Cyprotex has completed a major upgrade of the software it uses to predict pharmacokinetic changes caused by drug compounds.

The company said the Cloe PK software has already been shown to be able to predict via computer modelling aspects of human pharmacokinetics better than extrapolating results from studies using animals.

The software uses 27 parameters in the software’s analysis and that the upgrade has improved 16 of these. It added that enhancements had been facilitated through working with some of its major clients who provided the firm with results from animal tests as a comparable dataset.

Cyprotex’s chief scientific officer, Dr Katya Tsaioun, said: “Cyprotex continues to refine the Cloe PK software and this latest enhancement increases the model’s reliability and usability.

“Cloe PK speeds up the process of selecting compound candidates to create a drug and it reduces the need for expensive and time-consuming animal pharmacokinetic studies.”